drugset / Trial / NCT00785395

Up-Down Oxytocin Infusion

NCT00785395

Phase 4 Completed 40 enrolled IWK Health Centre
NaSingle-groupDouble-blindPrevention

Summary

This study is designed to determine the minimum effective dose (ED90) of infusions of oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for additional uterotonics, in low risk parturients presenting for an elective CD. The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.

Timeline

Start
2008-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 15 iu Intravenous

Indications